(Q33362775)

English

Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Anna Koumarianou

object named as

Anna Koumarianou

5

0 references

author name string

Dimitrios Pectasides

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Melina Pectasides

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimitrios Farmakis

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Asimina Gaglia

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Maria Nikolaou

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Maria Koumpou

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Panteleimon Kountourakis

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Georgios Papaxoinis

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Panagiota Mitrou

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Theofanis Economopoulos

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sotirios A Raptis

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 October 2004

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

165-172

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Treatment of recurrent ovarian cancer: increasing options--"recurrent" results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Oxaliplatin in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.029

7 January 2021

Identifiers

10.1016/J.YGYNO.2004.06.029

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33362775&oldid=1584686934"